Table 2.

Point Estimates and 95% CIs for Group-Specific Geometric Mean Fold-Rrises (GMFRs) and Adjusted Geometric Mean Ratios (aGMRs, Comparing High Dose [HD-TIV] to Standard Dose [SD-QIV]), Shown for Each Antigen at Each Follow-up Visit

	GMFR (95% CI)		aGMR (95% CI)
	SD-QIV (n = 64)	HD-TIV (n = 60)	(HD-TIV/SD-QIV)
A/H1N1
Visit 2	2.33 [1.54, 3.53]	2.17 [1.48, 3.18]	1.06 [0.62, 1.82]
Visit 3	4.08 [2.33, 7.14]	4.45 [2.67, 7.39]	1.14 [0.65, 1.98]
Visit 4	2.22 [1.28, 3.86]	2.51 [1.59, 3.97]	1.07 [0.60, 1.89]
A/H3N2
Visit 2	1.72 [1.22, 2.43]	2.81 [1.82, 4.35]	1.55 [0.90, 2.69]
Visit 3	3.53 [2.14, 5.83]	7.24 [4.12, 12.7]	2.03 [1.16, 3.59]
Visit 4	1.64 [1.03, 2.62]	3.33 [2.05, 5.40]	1.87 [1.05, 3.34]
B/Victoria
Visit 2	1.69 [1.21, 2.36]	1.80 [1.30, 2.50]	1.10 [0.70, 1.75]
Visit 3	2.86 [1.79, 4.59]	4.34 [2.76, 6.84]	1.63 [1.02, 2.61]
Visit 4	1.37 [0.89, 2.13]	2.39 [1.54, 3.69]	1.63 [1.00, 2.65]
B/Yamagata a
Visit 2	2.12 [1.40, 3.22]	0.94 [0.74, 1.19]	0.45 [0.30, 0.70]
Visit 3	2.61 [1.63, 4.18]	1.30 [0.96, 1.76]	0.52 [0.34, 0.81]
Visit 4	1.47 [0.95, 2.26]	0.86 [0.59, 1.26]	0.53 [0.33, 0.83]

Visit 2 titers are measured at a target window of 28–42 days following the first dose (prior to the second dose), visit 3 titers are measured at a target window of 28–42 days following the second dose, and visit 4 titers are measured at a target window of 138–222 days following visit 3. Bolding indicates statistical significance at the 0.05 level (two-sided).

Abbreviations: CI, confidence interval; HD-TIV, high-dose trivalent; SD-QIV, standard-dose quadrivalent.

^aB/Yamagata is not included in HD-TIV.